Estrogen Receptor-negative/progesterone Receptor-positive and Her-2 Negative Breast Cancer Might No Longer Be Classified as Hormone Receptor Positive Breast Cancer

Hongjuan Zheng

Affiliated jinhua hospital, zhejiang university school of medicine

Chenyang Ge

Affiliated jinhua hospital, zhejiang university school of medicine

Haiping Lin

Affiliated jinhua hospital, zhejiang university school of medicine

Lunpo Wu

Second affiliated hospital of zhejiang university school of medicine

Qinghua Wang

Affiliated jinhua hospital, zhejiang university school of medicine

Shishi Zhou

Affiliated jinhua hospital, zhejiang university school of medicine

Wanfen Tang

Affiliated jinhua hospital, zhejiang university school of medicine

Xia Zhang

Affiliated jinhua hospital, zhejiang university school of medicine

Xiayun Jin

Affiliated jinhua hospital, zhejiang university school of medicine

Xifeng Xu

Affiliated jinhua hospital, zhejiang university school of medicine

Zhongwu Hong

Affiliated jinhua hospital, zhejiang university school of medicine

Jianfei Fu (✉ 11218276@zju.edu.cn)

Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, 351 Mingyue Road, Jinhua 321000, Zhejiang Province, China <https://orcid.org/0000-0002-3036-1056>

Jinlin Du

Affiliated jinhua hospital, zhejiang university school of medicine

Research article

Keywords: Breast cancer, sPR positive, the annual hazard rate of death, cancer-specific survival

Posted Date: October 5th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-73479/v1>

Version of Record: A version of this preprint was published at International Journal of Clinical Oncology on April 10th, 2022. See the published version at <https://doi.org/10.1007/s10147-022-02158-0>.

Abstract

Background: The estrogen receptor (ER)-negative/progesterone receptor (PR)-positive (sPR positive) phenotype is an infrequent and independent biological entity. However, the prognosis of patients with sPR positive and her-2 negative phenotype is still controversial, and it is not always easy to decide treatment strategies for them.

Methods: Patients during 2010–2014 were identified from Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method was used to evaluate cancer-specific survival (CSS). The propensity score matching (PSM) method was used to balance differences of characteristics in groups. The Life-Table method was used to calculate 5-year CSS rates and the annual hazard rate of death (HRD).

Results: A total of 97,527 patients were included, and only 745 (0.76%) patients were sPR positive phenotype. The majority of sPR positive breast cancer were basal-like subtype. Survival analysis showed that the sPR positive breast cancer had similar prognosis comparing to ER-negative/PR-negative (dHR negative) breast cancer, and had the highest HRD during the initial 1-2 years of follow-up, then maintained the HRD of almost zero during the late years of follow-up.

Conclusions: The patients with sPR positive and her-2 negative breast cancer, similar to dHR negative breast cancer, had a worse survival, and could benefit from chemotherapy significantly. However, the escalating endocrine therapy was not recommended for sPR positive patients. The patients with sPR positive should be excluded from future clinical trials concerning endocrine therapy.

Background

Breast cancer is the greatest threat to women's health and the leading cause of cancer death in young women. In 1973, estrogen receptor (ER) has been recognized as a strong indicator of response to endocrine therapy [1]. Then, ER and progesterone receptor (PR) were gradually established prognostic factors in female breast cancer [2–6]. And steroid hormone receptors were shown to be the strongest predictive markers of response to endocrine therapy in breast cancer [7–10].

There are four hormone-receptor status (HoR status) phenotypes, and the ER-negative/PR-positive (sPR positive) phenotype is infrequent, accounting for 1.0%- 4.10% of all types of malignant breast cancer [11–16]. The existence of the sPR positive breast cancer used to be controversial. Then, the sPR positive phenotype was proved by re-evaluating ER and PR status through immunohistochemical staining (IHC)[13, 17] or analyzing PAM50 expression signature and mRNA level of ESR1 [11, 18]. Besides, Borrás and his co-authors established the sPR positive Evsa-T cell line, which also demonstrated the presence of sPR positive breast cancer [19].

Unlike other types of breast cancer, the sPR positive breast cancer had unique clinicopathological characteristics and controversial prognosis[17, 20, 21]. Ke-Da et al. showed that the survival of the sPR positive phenotype was similar to the ER-negative/PR-negative (dHR negative) phenotype [22], while, Ethier et al. indicated that the survival of sPR positive patients was similar to ER-positive/PR-positive (dHR positive) patients [12]. The prognosis of patients with sPR positive and her-2 negative breast cancer is still controversial; therefore, we aim to explore the true prognosis of patients with sPR positive through large-sample clinical data analysis.

In the current study, we systemically studied the clinical features, survival outcomes and the annual hazard rate of death (HRD) of patients with sPR positive and her-2 negative breast cancer.

Methods

2.1 Study Population

The Surveillance, Epidemiology, and End Results (SEER) database was established by the National Cancer Institute with the aim of collecting information about cancer incidence and survival. This national programme includes 18 population-based cancer registries among 14 states across the United States, representing about 30% of the population of the United States. We obtained permission to access the research data (reference number, 12296-Nov2018). The study was approved by the ethics committee of Zhejiang University Jinhua hospital. We used SEER*Stat version 8.3.5 (<http://seer.cancer.gov/seerstat>) to identify patients diagnosed with breast cancer from January 2010 to December 2014. Patients diagnosed after 2014 were excluded to ensure an adequate duration of follow-up. We retrieved records of year and age at diagnosis, gender, race, insurance, marital status, histological type, differentiated grade, location of tumor, T-classification, N-classification, stage TNM, administration of radiotherapy, administration of chemotherapy, ER, PR, her-2, survival months, and cause of death.

The specific inclusion criteria were as follows: (1) site record ICD-O-3 was limited to breast cancer (C500-506; C508-509); (2) gender was limited to female; (3) histological type ICD-O-3 was limited to infiltrative ductal cancer, infiltrative lobular cancer or mixed with both of them (8500/3, 8520/3, 8521/3, 8522/3, 8524/3, 8541/3); (4) the survival time of patients exceeded 1 month; (5) patients were without distant metastasis; (6) the age at diagnosis was limited from 20 to 80; (7) patients were not multiple primary tumors. The exclusion criteria were as follows: (1) patients were lacking documentation of race, marital status, insurance status, differentiated grade (included grade IV), location of tumor, ER, PR, her-2, T-classification, N-classification; (2) patients were her-2 positive; (3) patients received neoadjuvant therapy; (4) the cause of death was unknown (For the detailed inclusion and exclusion criteria, see the **Supplemental Fig. 1**).

2.2 Variable Declaration

Age was regrouped as 20–40 years old, 41–60 years old, 61–70 years old, 71–80 years old, according to our previous study analysis result [23]. Race was divided into white, black and other. Marital status was regrouped as married, single and divorced. Insurance status was divided into insured, medicaid and uninsured. Histological type was grouped as infiltrative ductal cancer (IDC), infiltrative lobular cancer (ILC) and mixture (IDC&ILC). The variable of chemotherapy was only classified as “yes” or “no/unknown”, since SEER treatment information cannot accurately distinguish between “no treatment” and “unknown if patients received treatment” [24]. All cases were regrouped according to the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system. The HoR status of the tumor was stratified to dHR positive, ER-positive/PR-negative (sER positive), sPR positive, and dHR negative.

2.3 Statistical analyses

The distribution of clinicopathological characteristics in different HoR status groups was analyzed using Chi-Squared tests. Propensity score matching method (PSM) was used to balance differences of characteristics between chemotherapy and non-chemotherapy groups. The propensity score was calculated by logistic regression including covariates of HoR status, T-Classification and N-Classification. The “Matchit” package in R software was used as the nearest method with ratio 1:1 and caliper = 0.0001. The cancer-specific survival (CSS), the primary endpoint, was calculated from the date of diagnosis to the date of death of breast cancer. Death attributed to other causes was defined as a censored observation. Survival curves were generated using the Kaplan-Meier method, and the log-rank test was carried out to evaluate the survival differences between groups. The 5-year CSS rates were calculated by Life-Table method. The hazard ratio (HR) of the variables for CSS was estimated using Cox proportional hazard regression model. The Life-Table method was used to calculate HRD. The HRD were plotted at each 6-months interval after diagnosis until month 79, with a total of 13 intervals (intervals 0 to 79). Interpolation was conducted using a locally weighted scatter plot smoothing (LOWESS) function.

R3.5.2 software (<http://www.r-project.org/>) was used to perform the statistical analyses. When the two-sided P value was less than 0.05, the difference was considered statistically significant.

Results

3.1 Clinicopathological characteristics of patients with her-2 negative breast cancer

We identified 97,527 eligible patients with her-2 negative breast cancer from SEER. The endpoint date of the follow-up was November 2014, with a median follow-up of 48 months (range: 1 to 83 months). There were 0.86% women diagnosed with sPR positive in HoR positive resectable breast cancer, and 0.76% in all resectable breast cancer.

Compared with the sER positive, patients with sPR positive were younger at time of diagnosis (median age 55 versus 62 years, $P<0.001$), less likely had infiltrative lobular carcinoma (1.61% versus 13.38%, $P<0.001$), had more poorly-differentiated (80.27% versus 36.71%, $P<0.001$) as well as late-stage breast cancer. More patients with sPR positive received chemotherapy (73.56 vs. 45.27%, $P<0.001$). However, patients with dHR negative and sPR positive tumors had similar clinicopathological characteristics. The detail information was indicated in **Table 1**.

3.2 Univariate and multivariate analysis of CSS

In total, 3,454 (3.07%) patients died of breast cancer. The 5-year CSS rates of patients with sPR positive breast cancer and dHR negative breast cancer were 89.03 % and 87.69%, respectively. The survival of patients with sER positive and dHR positive were much better, with 5-year CSS rates of 93.57% and 97.81% ($P<0.001$, **Figure 1**).

Multivariate analysis revealed that HoR status was an independent prognostic factor. Compared with sPR positive breast cancer, the dHR positive and sER positive breast cancer had favorable survivals (HR=0.29, 95% CI, 0.22-0.36; $P<0.001$; HR=0.65, 95% CI, 0.51-0.84; $P<0.001$, respectively). The detail results were indicated in **Table 2**.

3.3 The hazard rate of death (HRD) in different phenotypes of breast cancer

The dHR positive phenotype continued to have a low level of the HRD during the disease progression. The HRD of sPR positive phenotype was higher than the other three phenotypes during the initial 1-2 years of follow-up, and then descended rapidly and successively crossed with the other three phenotypes during the 3-5 years of follow-up. However, the HRD of sPR positive phenotype decreased nearly to zero during the later years of follow-up time (**Figure 2**).

3.4 Analyzing treatment benefits according to HoR status in the PSM cohort

In the initial data, the sample size of patients in the chemotherapy group was fewer than non-chemotherapy group. Also, there were different baseline characteristics between these two groups (**Table 1**). Therefore, the PSM method was used to balance differences of baseline characteristics. A total of 21,208 patients with chemotherapy were matched with 21,208 patients without chemotherapy (**Supplemental figure 2**). All covariates included were well balanced between chemotherapy and non-chemotherapy groups in the PSM cohort (**Supplemental table 1**).

In the PSM cohort, patients with sPR positive and dHR negative phenotypes benefited significantly from chemotherapy both with $P<0.001$, while patients with sER positive could not benefit from chemotherapy with $P=0.052$ (**Figure 3**). Furthermore, we performed an interaction analysis using Cox model between the chemotherapy and HoR status in the PSM cohort (**Figure 4**). The results showed that the sPR positive phenotype benefited more from chemotherapy than dHR negative phenotype (P for interaction = 0.001). Besides, in the non-chemotherapy group, patients with sPR positive phenotype had worse survival than dHR negative phenotype with $P=0.034$. In the patients with chemotherapy, patients with sPR positive had similar prognosis to dHR negative with $P=0.614$ (**Supplemental figure 3**).

3.5 Systematic review of the intrinsic subtypes with sPR positive phenotype

Intrinsic molecular subtypes of breast cancer have been thoroughly studied and can indicate the existence of sPR positive phenotype [11, 12, 22]. In total, the sPR positive phenotype had a higher likelihood of being the basal-like subtype (46.15%). Normal-like and her-2 positive subtypes comprised a small proportion, accounting for 4.41%, 9.89%, respectively (Table 3).

Discussion

Breast cancer with sPR positive is a rare and a biologically distinct subgroup [12, 20, 22]. When considering the causes of sPR positive breast cancer, the mechanisms are quite complicated [19, 25–27]. The secondary loss of ER is one of the hypotheses. Higher estrogen levels in premenopausal females could downregulate the expression of ER protein [26]. Previous studies showed that patients with sPR positive phenotype were more diagnoses in young, who have a relatively higher estrogen level. What's more, patients with sPR positive phenotype were more often with her-2 positive [17, 21] and higher grade [20], which were consistence with our study.

In this study, we identified eligible female patients with her-2 negative breast cancer from SEER to explore the outcomes of patients with sPR positive phenotype. Our results showed that patients with sPR positive phenotype had unfavorable prognosis which was similar with patients dHR negative phenotype, which was consistent with other studies [20, 22, 28]. We have investigated detail clinicopathologic features of sPR positive phenotype and found that the majority of sPR positive breast cancer occurred in younger women with poorly differentiated and late-stage tumors and were rarely of classical lobular type. Besides, the study of Rakha showed that sPR positive phenotype was more frequently associated with biomarkers of poor prognosis such as positive 53 and basal cytokeratin and reduced E-cadherin expression [20]. All above suggested that sPR positive phenotype is a more aggressive phenotype.

Perou and his co-authors [29] identified four breast cancer subtypes: the basal-like, HER2-enriched, luminal-A, luminal-B and the normal-like breast cancer. Majority of sPR positive tumors tend to be lower mRNA level of ESR1 and basal-like molecular subtype according to Ethier's study (N = 31, 58.49%) [12] and Itoh's study (N = 13, 65%) [18]. Compared with luminal subtypes, patients with basal-like subtype had a poorer survival [30–35] and benefited least from tamoxifen endocrine therapy [36, 37]. Besides, patients with basal-like subtype benefited better from chemotherapy with paclitaxel and anthracycline than luminal subtypes [32, 38–40]. Aleix's study highlighted the higher chemotherapy sensitivity of basal-like subtype [34]. Above all, these results suggest that sPR positive breast cancer might tend to be more sensitive to chemotherapy and less effective in endocrine therapy. Furthermore, these speculations could be confirmed in our study. The Kaplan-Meier and interaction analyses of chemotherapy in different HoR status revealed that patients with sPR positive phenotype could benefit more from chemotherapy when compared with sER positive and dHR negative phenotypes. The particular mechanism of the highly sensitive to chemotherapy of sPR positive phenotype is still unclear. We speculate that it might be related to inadequate chemotherapy to the patients with sPR positive phenotype. What's more, the HRD vividly showed that sPR positive breast cancer suffered a high death risk at the initial 1–2 years. Above all, we proposed that patients with sPR positive should be given more intense chemotherapy just like dHR negative at the beginning.

The study of Bardou and his co-authors showed that patients with sPR positive phenotype, compared with the other three phenotypes, had the worst prognosis when received systemic endocrine therapy in the database of Program Project [41]. Davies's study also revealed that 1236 patients with sPR positive breast cancer did not benefit from 5 years of tamoxifen endocrine therapy with $P = 0.35$ [42]. These results showed that sPR positive breast cancer had less sensitivity of endocrine therapy.

According to the HRD, for sPR positive patients, the risk of tumor death was decreased to nearly zero after 5 years. On the contrary, the HRD of dHR positive and sER positive patients were both continued to stabilized in relatively high levels during the follow-up time. Therefore, for patients with sPR positive, it is advisable to de-escalate rather than highlight the endocrine therapy, and for dHR positive and sER positive patients the escalating endocrine therapy might be more necessary to reduce the risk of recurrence or tumor death in the later time.

In conclusion, patients with sPR positive and her-2 negative phenotype had similar prognosis with triple-negative phenotype. Patients with sPR positive phenotype had higher sensitivity of chemotherapy and lower response to endocrine therapy. In future clinical trials of breast cancer concerning endocrine therapy, patients with sPR positive should be treated with caution or even be excluded. However, further prospective studies referring to response of sPR positive breast cancer to endocrine therapy are recommended.

Declarations

Ethics approval and consent to participate

Not applicable. Because this article does not contain any studies with human participants or animals performed by any of the authors.

Consent for publication

Not applicable.

Competing interests

All authors have declared no conflicting interests.

Funding statement

Funding: This study was funded by the major program of the Jinhua Municipal Science & Technology Bureau (grant number 2019-3-004) and the key program of the Jinhua Municipal Science & Technology Bureau (grant number 2014-3-008).

The funders had roles in conceptualization, review and editing of the manuscript.

Authors' contributions

HJ. Z and CY. G: Data curation, Writing- Original draft preparation.

HP. L: Methodology.

LP. W: Writing - Review & Editing

SS. Z: Software.

WF. T and QH. W: Validation.

X. Z: Formal analysis.

XY. J: Project administration.

XF. X: Visualization.

ZW. H: Funding acquisition

JF. F and JL. D: Conceptualization, Writing - Review & Editing, Supervision.

All authors have read and approved the manuscript.

Acknowledgements

We thank professor Barry Nelkin in the Department of Oncology, Johns Hopkins University School of Medicine, for his constructive comments and language editing.

Obtaining Data

All data in this study was identified from the Surveillance, Epidemiology, and End Results (SEER) database (<http://seer.cancer.gov/>).

References

1. McGuire WL. Estrogen receptors in human breast cancer. *J Clin Invest.* 1973;52(1):73-7. doi: 10.1172/JCI107175. PubMed PMID: 4345203; PubMed Central PMCID: PMCPMC302228.
2. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, et al. Hormone receptors as prognostic factors in female breast cancer. *Ann Med.* 1991;23(6):643-8. doi: 10.3109/07853899109148097. PubMed PMID: 1777219.
3. May E, Mouriessse H, May-Levin F, Qian JF, May P, Delarue JC. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. *British journal of cancer.* 1990;62(3):430-5. doi: 10.1038/bjc.1990.312. PubMed PMID: 1976381; PubMed Central PMCID: PMCPMC1971463.
4. Raemaekers JM, Beex LV, Koenders AJ, Pieters GF, Smals AG, Benraad TJ, et al. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. *Breast cancer research and treatment.* 1985;6(2):123-30. doi: 10.1007/bf02235743. PubMed PMID: 4052639.
5. Chevallier B, Heintzmann F, Mosseri V, Dauce JP, Bastit P, Graic Y, et al. Prognostic Value of Estrogen and Progesterone Receptors in Operable Breast-Cancer - Results of a Univariate and Multivariate-Analysis. *Cancer-Am Cancer Soc.* 1988;62(12):2517-24. doi: Doi 10.1002/1097-0142(19881215)62:12<2517::Aid-Cncr2820621211>3.0.Co;2-9. PubMed PMID: WOS:A1988R257000010.
6. Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R. Significance of Estrogen and Progesterone Receptors, Disease-Free Interval, and Site of 1st Metastasis on Survival of Breast-Cancer Patients. *Cancer-Am Cancer Soc.* 1985;56(7):1696-700. doi: Doi 10.1002/1097-0142(19851001)56:7<1696::Aid-Cncr2820560738>3.0.Co;2-N. PubMed PMID: WOS:A1985AQR2000037.
7. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. *American journal of clinical pathology.* 2005;123(1):21-7. Epub 2005/03/15. doi: 10.1309/4wv79n2ghj3x1841. PubMed PMID: 15762276.
8. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. *Journal of Clinical Oncology.* 2003;21(10):1973-9. doi: 10.1200/Jco.2003.09.099. PubMed PMID: WOS:000182903400012.
9. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic-Significance of Progesterone-Receptor Levels in Estrogen Receptor-Positive Patients with Metastatic Breast-Cancer Treated with Tamoxifen - Results of a Prospective Southwest-Oncology-Group Study. *Journal of Clinical Oncology.* 1992;10(8):1284-91. doi: Doi 10.1200/Jco.1992.10.8.1284. PubMed PMID: WOS:A1992JF66100013.
10. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The Value of Estrogen and Progesterone Receptors in the Treatment of Breast-Cancer. *Cancer-Am Cancer Soc.* 1980;46(12):2884-8. doi: Doi 10.1002/1097-0142(19801215)46:12<2884::Aid-Cncr2820461429>3.0.Co;2-U. PubMed PMID: WOS:A1980KX18500029.
11. Schroth W, Winter S, Buttner F, Goletz S, Faisst S, Brinkmann F, et al. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer

- phenotype. *Breast cancer research and treatment*. 2016;155(1):85-97. Epub 2015/12/10. doi: 10.1007/s10549-015-3651-5. PubMed PMID: 26650824.
12. Ethier JL, Ocana A, Rodriguez Lescure A, Ruiz A, Alba E, Calvo L, et al. Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study. *European journal of cancer*. 2018;94:199-205. doi: 10.1016/j.ejca.2018.02.018. PubMed PMID: 29573665.
 13. Kuroda H, Muroi N, Hayashi M, Harada O, Hoshi K, Fukuma E, et al. Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining. *Breast cancer (Tokyo, Japan)*. 2019;26(2):249-54. Epub 2018/08/02. doi: 10.1007/s12282-018-0898-9. PubMed PMID: 30066060; PubMed Central PMCID: PMC6394606.
 14. Cserni G, Francz M, Kalman E, Kelemen G, Komjathy DC, Kovacs I, et al. Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they? *Pathology oncology research : POR*. 2011;17(3):663-8. Epub 2011/01/27. doi: 10.1007/s12253-011-9366-y. PubMed PMID: 21267685.
 15. De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, et al. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2008;26(2):335-6; author reply 6-8. doi: 10.1200/JCO.2007.14.8411. PubMed PMID: 18182677.
 16. Shen T, Brandwein-Gensler M, Hameed O, Siegal GP, Wei S. Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. *Human pathology*. 2015;46(11):1776-84. Epub 2015/09/14. doi: 10.1016/j.humpath.2015.07.019. PubMed PMID: 26363528.
 17. Rhodes A, Jasani B. The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact? *Journal of clinical pathology*. 2009;62(1):95-6. doi: 10.1136/jcp.2008.060723. PubMed PMID: 19103868.
 18. Itoh M, Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, et al. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. *Breast cancer research and treatment*. 2014;143(2):403-9. doi: 10.1007/s10549-013-2763-z. PubMed PMID: 24337596.
 19. Borrás M, Lacroix M, Legros N, Leclercq G. Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers. *Cancer letters*. 1997;120(1):23-30. doi: 10.1016/s0304-3835(97)00285-1. PubMed PMID: 9570382.
 20. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2007;25(30):4772-8. doi: 10.1200/JCO.2007.12.2747. PubMed PMID: 17876012.
 21. Chan M, Chang MC, Gonzalez R, Lategan B, del Barco E, Vera-Badillo F, et al. Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. *PloS one*. 2015;10(7):e0132449. doi: 10.1371/journal.pone.0132449. PubMed PMID: 26161666; PubMed Central PMCID: PMC4498889.
 22. Yu KD, Jiang YZ, Hao S, Shao ZM. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer. *BMC medicine*. 2015;13:254. Epub 2015/10/07. doi: 10.1186/s12916-015-0496-z. PubMed PMID: 26437901; PubMed Central PMCID: PMC6394606.
 23. Fu J, Zhong C, Wu L, Li D, Xu T, Jiang T, et al. Young Patients with Hormone Receptor-Positive Breast Cancer Have a Higher Long-Term Risk of Breast Cancer Specific Death. *J Breast Cancer*. 2019;22(1):96-108. doi: 10.4048/jbc.2019.22.e13. PubMed PMID: 30941237; PubMed Central PMCID: PMC6394606.
 24. Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, et al. Comparison of SEER Treatment Data With Medicare Claims. *Med Care*. 2016;54(9):e55-64. doi: 10.1097/MLR.000000000000073. PubMed PMID: 24638121;

25. Hopp TA, Weiss HL, Hilsenbeck SG, Cui YK, Allred DC, Horwitz KB, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. *Clinical Cancer Research*. 2004;10(8):2751-60. doi: Doi 10.1158/1078-0432.Ccr-03-0141. PubMed PMID: WOS:000220933800024.
26. Martin MB, Saceda M, Lindsey RK. Regulation of estrogen receptor expression in breast cancer. *Adv Exp Med Biol*. 1993;330:143-53. doi: 10.1007/978-1-4615-2926-2_11. PubMed PMID: 8368130.
27. Koehorst SG, Jacobs HM, Thijssen JH, Blankenstein MA. Wild type and alternatively spliced estrogen receptor messenger RNA in human meningioma tissue and MCF7 breast cancer cells. *J Steroid Biochem Mol Biol*. 1993;45(4):227-33. doi: 10.1016/0960-0760(93)90336-u. PubMed PMID: 8499331.
28. Fan Y, Ding X, Xu B, Ma F, Yuan P, Wang J, et al. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer. *Medicine*. 2015;94(46):e2066. Epub 2015/11/19. doi: 10.1097/md.0000000000002066. PubMed PMID: 26579819; PubMed Central PMCID: PMC4652828.
29. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature*. 2000;406(6797):747-52. doi: 10.1038/35021093. PubMed PMID: 10963602.
30. Yin D, Wang YL, Wang YF, Yang L, Zhang L, Tang C, et al. Correlation between Clinical Pathology of Luminal B Breast Cancer and Determination of Estrogen Receptor, Progesterone Receptor and Her2 Expression Combined with Nuclear Morphology. *J Biol Regul Homeost Agents*. 2015;29(3):579-87. PubMed PMID: 26403396.
31. Liu S, Chapman JA, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, et al. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. *Breast cancer research and treatment*. 2015;149(2):439-48. doi: 10.1007/s10549-014-3259-1. PubMed PMID: 25552364.
32. Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. *Breast cancer research and treatment*. 2012;135(1):301-6. doi: 10.1007/s10549-012-2143-0. PubMed PMID: 22752290; PubMed Central PMCID: PMC413822.
33. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2007;13(8):2329-34. doi: 10.1158/1078-0432.CCR-06-1109. PubMed PMID: 17438091.
34. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. *Mol Oncol*. 2011;5(1):5-23. doi: 10.1016/j.molonc.2010.11.003. PubMed PMID: 21147047; PubMed Central PMCID: PMC4528267.
35. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A*. 2003;100(14):8418-23. doi: 10.1073/pnas.0932692100. PubMed PMID: 12829800; PubMed Central PMCID: PMC466244.
36. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, et al. A three-gene model to robustly identify breast cancer molecular subtypes. *Journal of the National Cancer Institute*. 2012;104(4):311-25. doi: 10.1093/jnci/djr545. PubMed PMID: 22262870; PubMed Central PMCID: PMC3283537.
37. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2012;18(16):4465-72. doi: 10.1158/1078-0432.CCR-12-0286. PubMed PMID: 22711706; PubMed Central PMCID: PMC4374363.
38. Sanchez-Munoz A, Plata-Fernandez Y, Fernandez M, Jaen-Morago A, Fernandez-Navarro M, de la Torre-Cabrera C, et al. Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological

complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients. Clin Transl Oncol. 2014;16(6):548-54. doi: 10.1007/s12094-013-1116-z. PubMed PMID: 24085576.

39. Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, et al. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol. 2011;41(7):867-75. doi: 10.1093/jjco/hyr081. PubMed PMID: 21719750.
40. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005;11(16):5678-85. doi: 10.1158/1078-0432.CCR-04-2421. PubMed PMID: 16115903.
41. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(10):1973-9. doi: 10.1200/JCO.2003.09.099. PubMed PMID: 12743151.
42. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (London, England). 2011;378(9793):771-84. Epub 2011/08/02. doi: 10.1016/s0140-6736(11)60993-8. PubMed PMID: 21802721; PubMed Central PMCID: PMC3163848.

Tables

Table 1 The characteristics of patients with her-2 negative breast cancer in different hormone receptor status

Risk factors	N (%)	ER+/PR+, N (%)	ER+/PR-, N (%)	ER-/PR+, N (%)	ER-/PR-, N (%)	<i>p</i> ^a
Total	97527	76521(78.46)	9162(9.39)	745(0.76)	11099(11.38)	
Age at diagnosis						<0.001
20-40	5057	3521(4.6)	412(4.5)	62(8.32)	1062(9.57)	
41-60	46071	36267(47.39)	3815(41.64)	424(56.91)	5565(50.14)	
61-70	29363	23178(30.29)	3119(34.04)	171(22.95)	2895(26.08)	
71-80	17036	13555(17.71)	1816(19.82)	88(11.81)	1577(14.21)	
Race						<0.001
White	78800	63117(82.48)	7059(77.05)	544(73.02)	8080(72.8)	
Black	9475	6001(7.84)	1173(12.8)	147(19.73)	2154(19.41)	
Others	9252	7403(9.67)	930(10.15)	54(7.25)	865(7.79)	
Marital status						<0.001
Married	61275	48398(63.25)	5586(60.97)	472(63.36)	6819(61.44)	
Single	14181	10962(14.33)	1309(14.29)	115(15.44)	1795(16.17)	
Divorced	22071	17161(22.43)	2267(24.74)	158(21.21)	2485(22.39)	
insurance						<0.001
Insured	86233	68046(88.92)	8047(87.83)	631(84.7)	9509(85.67)	
Medicaid	9970	7469(9.76)	1006(10.98)	102(13.69)	1393(12.55)	
Uninsured	1324	1006(1.31)	109(1.19)	12(1.61)	197(1.77)	
Histological type						<0.001
IDC	81531	62512(81.69)	7434(81.14)	721(96.78)	10864(97.88)	
ILC	9907	8560(11.19)	1226(13.38)	12(1.61)	109(0.98)	
IDC&ILC	6089	5449(7.12)	502(5.48)	12(1.61)	126(1.14)	
Differentiated grade						<0.001
Well	26503	24286(31.74)	2026(22.11)	14(1.88)	177(1.59)	
Moderate	45260	39568(51.71)	3773(41.18)	133(17.85)	1786(16.09)	
Poor	25764	12667(16.55)	3363(36.71)	598(80.27)	9136(82.31)	
T-Classification^b						<0.001
T1	66942	54691(71.47)	5857(63.93)	393(52.75)	6001(54.07)	
T2	26832	19158(25.04)	2838(30.98)	314(42.15)	4522(40.74)	
T3	3289	2384(3.12)	405(4.42)	27(3.62)	473(4.26)	
T4	464	288(0.38)	62(0.68)	11(1.48)	103(0.93)	
N-Classification^b						<0.001

N0	71234	55835(72.97)	6686(72.98)	533(71.54)	8180(73.7)
N1	20418	16319(21.33)	1820(19.86)	173(23.22)	2106(18.97)
N2	4021	3072(4.01)	399(4.35)	23(3.09)	527(4.75)
N3	1854	1295(1.69)	257(2.81)	16(2.15)	286(2.58)
Stage					<0.001
Stage I	58453	47727(62.37)	5147(56.18)	332(44.56)	5247(47.27)
Stage II	31773	23390(30.57)	3206(34.99)	355(47.65)	4822(43.45)
Stage III	7301	5404(7.06)	809(8.83)	58(7.79)	1030(9.28)
Chemotherapy					<0.001
No/Unknown	62979	55210(72.15)	5014(54.73)	197(26.44)	2558(23.05)
Yes	34548	21311(27.85)	4148(45.27)	548(73.56)	8541(76.95)
Radiotherapy					<0.001
No	37847	28643(37.43)	3676(40.12)	327(43.89)	5201(46.86)
Yes	59680	47878(62.57)	5486(59.88)	418(56.11)	5898(53.14)

Abbreviations: N: Number. IDC: Infiltrating duct carcinoma. ILC: Infiltrating lobular carcinoma. ER: Estrogen receptor. PR: Progesterone receptor.

^a P values obtained from the χ^2 test. All statistical tests were two-sided.

^b The T classification was subclassified as T1, T2, T3, or T4 and the N classification was subclassified as N0, N1, N2, or N3 according to the 8th edition of the American Joint Committee on Cancer TNM staging system.

Table 2 Univariate and multivariate analysis for CSS in patients with her-2 negative breast cancer based on Cox proportional hazard model

Risk Factors	Univariate analysis	Multivariate analysis		
	HR (95%CI)	<i>P</i> ^a	HR (95%CI)	<i>P</i> ^a
Hormone receptor status				
ER+/PR+	0.15(0.12-0.20)	<0.001	0.29(0.22-0.36)	<0.001
ER+/PR-	0.49(0.38-0.63)	<0.001	0.65(0.51-0.84)	<0.001
ER-/PR+	Reference		Reference	
ER-/PR-	0.97(0.77-1.23)	0.827	0.97(0.77-1.23)	0.809
Age at diagnosis				
20-40	Reference		Reference	
41-60	0.58(0.51-0.67)	<0.001	0.97(0.84-1.11)	0.632
61-70	0.57(0.50-0.66)	<0.001	1.25(1.08-1.46)	0.003
71-80	0.79(0.68-0.92)	0.002	1.71(1.46-2.01)	<0.001
Race				
White	Reference		Reference	
Black	2.17(1.98-2.38)	<0.001	1.21(1.10-1.33)	<0.001
Others	0.65(0.55-0.76)	<0.001	0.67(0.57-0.78)	<0.001
Marital status				
Married	Reference		Reference	
Single	1.56(1.42-1.72)	<0.001	1.16(1.05-1.29)	0.004
Divorced	1.47(1.35-1.60)	<0.001	1.19(1.09-1.30)	<0.001
insurance				
Insured	Reference		Reference	
Medicaid	2.11(1.92-2.32)	<0.001	1.37(1.24-1.51)	<0.001
Uninsured	1.85(1.44-2.39)	<0.001	1.16(0.90-1.50)	0.255
Histological type				
IDC	Reference		Reference	
ILC	0.87(0.77-0.99)	0.031	1.09(0.95-1.25)	0.244
IDC&ILC	0.78(0.66-0.92)	0.003	1.04(0.87-1.23)	0.681
Differentiated grade				
Well	Reference		Reference	
Moderate	2.95(2.49-3.50)	<0.001	1.89(1.59-2.24)	<0.001
Poor	12.97(11.03-15.24)	<0.001	4.14(3.47-4.94)	<0.001
T-Classification				

T1	Reference	Reference		
T2	4.56(4.20-4.96)	<0.001	1.62(1.43-1.83)	<0.001
T3	9.65(8.56-10.89)	<0.001	2.34(1.97-2.77)	<0.001
T4	20.43(16.76-24.92)	<0.001	3.06(2.41-3.89)	<0.001
N-Classification				
N0	Reference	Reference		
N1	3.01(2.76-3.29)	<0.001	2.05(1.84-2.28)	<0.001
N2	8.25(7.41-9.17)	<0.001	3.66(2.90-4.62)	<0.001
N3	15.22(13.56-17.08)	<0.001	5.52(4.39-6.93)	<0.001
Stage				
Stage I	Reference	Reference		
Stage II	4.55(4.12-5.03)	<0.001	1.54(1.31-1.81)	<0.001
Stage III	16.30(14.70-18.08)	<0.001	1.96(1.49-2.57)	<0.001
Chemotherapy				
No/Unknown	Reference	Reference		
Yes	3.49(3.23-3.77)	<0.001	0.90(0.82-0.98)	0.022
Radiotherapy				
No	Reference	Reference		
Yes	0.61(0.57-0.65)	<0.001	0.72(0.66-0.77)	<0.001

Abbreviations: CSS: Cancer-specific survival. HR: Harzard ratio. CI: Confidence index. IDC: Infiltrating duct carcinoma. ILC: Infiltrating lobular carcinoma. ER: Estrogen receptor. PR: Progesterone receptor.

^a P values obtained from the χ^2 test. All statistical tests were two-sided.

Table 3 Summary of characteristics and intrinsic subtype distribution of the included studies

Author	Year	Nation	Original Her-2	Number of sPR positive	Luminal-A (%)	Luminal-B (%)	Basal-like (%)	HER2-enriched (%)	Normal-like (%)
Ethier	2018	Canada & Spain	Negative	23	12(52.17)	4(17.39)	3(13.04)	4(17.39)	-
Schroth	2016	Germany	unknown	15	4(26.67)	1(6.67)	8(53.33)	1(6.67)	1(6.67)
Ke-Da Yu	2015	China	Negative	53	9(16.98)	7(13.21)	31(58.49)	4(7.55)	2(3.77)
Total	-	-	-	91	25(27.47)	12(13.19)	42(46.15)	9(9.89)	3(4.41)

Figures

Figure 1

Kaplan-Meier estimate for breast cancer patients with her-2 negative. The patients with sPR positive phenotype had similar prognosis comparing to the dHR negative phenotype with $P=0.892$. The patients with sER positive or dHR positive had obviously better survival than the sPR positive with $P<0.001$.

Figure 2

The annual hazard rate of death (HRD) for breast cancer patients with her-2 negative. The HRD of sPR positive phenotype was the highest in all phenotypes during the initial 1-2 years of follow-up, and then descended rapidly and successively crossed with the other three phenotypes during the 3-5 years of follow-up. Finally, the HRD of sPR positive phenotype decreased nearly to zero during the later years of follow-up time.

Figure 3

Chemotherapy benefits in different HR status phenotypes in the PSM cohort with her-2 negative breast cancer. The patients with sER positive phenotype could not benefit from chemotherapy with $P=0.052$ (B), while patients with sPR positive and dHR negative phenotypes benefited significantly from chemotherapy both with $P<0.001$ (C and D).

Figure 4

Interaction analysis using Cox model between the hormone receptor status and chemotherapy in the PSM cohort with her-2 negative breast cancer.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementalfigure1.tif](#)
- [Supplementalfigure2.tif](#)
- [Supplementalfigure3.tif](#)
- [Supplementaltable1.docx](#)